Press Coverage

The one-trial era: what the FDA’s shift signals for the future of drug development

The FDA is shifting toward approving drugs based on a single pivotal trial supported by…

CertaraMay 6, 2026

Blog

The Psychedelic Executive Order and the New U.S. Push on Psychedelic Research And What It Actually Means for Scientists

Learn how the Psychedelic Executive Order is shaping the U.S. push on psychedelic research, accelerating…

CertaraMay 5, 2026

Blog

How Pharma Can Transition to Non-animal Studies for Investigational Drugs

Pharma companies can ease the transition to non-animal studies for investigational drugs by leveraging NAMs…

CertaraMay 5, 2026

Publication

Understanding quantitative effects of anti-amyloid therapies on tau biomarkers and functional outcome

QSP modeling reveals how anti-amyloid therapies impact tau biomarkers and cognitive outcomes in Alzheimer’s disease.

CertaraMay 4, 2026

Poster

Modeling CAR-T Outcomes in Multiple Myeloma

Learn how QSP modeling predicts CAR-T therapy outcomes, identifies patient-specific response drivers, and supports multi-antigen…

CertaraMay 4, 2026

Blog

GxP Compliance in the Cloud: What IT Teams Need to Rethink

Learn how GxP validation works in modern SaaS and cloud environments, with best practices for…

CertaraMay 4, 2026

Poster

Modeling T-cell Exhaustion in Immunotherapy

Discover how QSP modeling predicts T-cell exhaustion, relapse risk, and optimal dosing strategies for T-cell…

CertaraMay 4, 2026

Poster

Modeling Hematopoiesis in MDS and AML with QSP

Discover a mechanistic QSP platform model of hematopoiesis to evaluate therapies in MDS and AML,…

CertaraMay 1, 2026

Blog

Optimize Readiness for MHRA-NICE Aligned Pathway

Achieve HTA and regulatory success in the MHRA–NICE pathway through early evidence alignment.

CertaraMay 1, 2026

Blog Knowledge Base

Understanding LC/MS/MS

Discover LC/MS/MS applications in therapy development and bioanalytical method development for robust, compliant pharmaceutical research.

CertaraMay 1, 2026

The one-trial era: what the FDA’s shift signals for the future of drug development

The Psychedelic Executive Order and the New U.S. Push on Psychedelic Research And What It Actually Means for Scientists

How Pharma Can Transition to Non-animal Studies for Investigational Drugs

Understanding quantitative effects of anti-amyloid therapies on tau biomarkers and functional outcome

Modeling CAR-T Outcomes in Multiple Myeloma

GxP Compliance in the Cloud: What IT Teams Need to Rethink

Modeling T-cell Exhaustion in Immunotherapy

Modeling Hematopoiesis in MDS and AML with QSP

Optimize Readiness for MHRA-NICE Aligned Pathway

Understanding LC/MS/MS

Newsletter sign up

Quick links

Solutions

Contact